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Surface bioengineering of diatomite based
nanovectors for efficient intracellular uptake and
drug delivery†
Monica Terracciano,a,b,c Mohammad-Ali Shahbazi,c Alexandra Correia,c Ilaria Rea,a
Annalisa Lamberti,d Luca De Stefano*a and Hélder A. Santos*c
Diatomite is a natural porous silica material of sedimentary origin. Due to its peculiar properties, it can be
considered as a valid surrogate of synthetic porous silica for nano-based drug delivery. In this work, we
exploit the potential of diatomite nanoparticles (DNPs) for drug delivery with the aim of developing a suc-
cessful dual-biofunctionalization method by polyethylene glycol (PEG) coverage and cell-penetrating
peptide (CPP) bioconjugation, to improve the physicochemical and biological properties of the particles,
to enhance the intracellular uptake in cancer cells, and to increase the biocompatibility of 3-aminopropyl-
triethoxysilane (APT) modified-DNPs. DNPs-APT-PEG-CPP showed hemocompatibility for up to 200 µg
mL−1 after 48 h of incubation with erythrocytes, with a hemolysis value of only 1.3%. The cytotoxicity of
the modified-DNPs with a concentration up to 200 µg mL−1 and incubation with MCF-7 and
MDA-MB-231 breast cancer cells for 24 h, demonstrated that PEGylation and CPP-bioconjugation can
strongly reduce the cytotoxicity of DNPs-APT. The cellular uptake of the modified-DNPs was also evalu-
ated using the above mentioned cancer cell lines, showing that the CPP-bioconjugation can considerably
increase the DNP cellular uptake. Moreover, the dual surface modification of DNPs improved both the
loading of a poorly water-soluble anticancer drug, sorafenib, with a loading degree up to 22 wt%, and
also enhanced the drug release profiles in aqueous solutions. Overall, this work demonstrates that the
biofunctionalization of DNPs is a promising platform for drug delivery applications in cancer therapy as a
result of its enhanced stability, biocompatibility, cellular uptake, and drug release profiles.
Introduction
Nanomedicine is an innovative research field combining nano-
technology and medicine, radically changing the healthcare
drug delivery landscape, in particular in cancer treatment.1
The application of nanotechnology in cancer therapy is
expected to result from more patient compliance, making the
therapy more efficient and painless, avoiding problems associ-
ated with conventional drug formulations. Thus, the aim of
nanomedicine in cancer therapy is the production of nano-
scale particles to enhance the bioavailability of drug mole-
cules, improving the tumor-targeting ability and reducing the
systemic drug toxicity.
Over the last few decades, great efforts have been made in
the development of innovative drug delivery systems currently
used in clinical and preclinical studies.2–4 Nanoparticle (NP)-
based drug delivery systems have provided many advantages
over conventional drug formulations, including enhanced
solubility of poorly-water soluble drugs, improved pharmaco-
kinetic profiles of drugs, controlled drug release, and simul-
taneous delivery of drugs for combination therapy to reduce
the drug resistance.5–7 Several types of organic, inorganic and
hybrid NPs, including dendrimers, liposomes, polymer
micelles, nanogels, carbon nanotubes, porous silicon (PSi)/
silica NPs, gold NPs, and magnetic NPs have been exploited
for drug delivery applications.8–13 Among them, PSi-based NPs
are the most used inorganic NPs in biomedical applications
due to their unique features such as controllable pore size,
high surface area, thermal stability, chemical inertness, bio-
compatibility, high loading capability, excellent biodegradabi-
lity, adaptable dissolution kinetics, and controllable drug
release profiles.1,14,15
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In recent years, emerging natural porous materials for bio-
medical applications have also been suggested to overcome
the shortcomings of the synthetic porous materials, finding in
diatomite a viable surrogate.16–19 Diatomite is a cheap fossil
compound formed by fragments of diatom siliceous skeletons,
with similar physicochemical properties as those of man-made
fabricated PSi.20,21 Due to its peculiar properties, such as
ordered pore structures, amorphous silica, high surface area,
tailorable surface chemistry, high permeability, biocompatibi-
lity, non-toxicity, low cost, optical and photonic properties,
diatomite has been used in different applications, including
optics,22,23 photonics,23 filtration,24 sensing and biosensing,25
and protein separation.26 The main constituent of diatomite is
amorphous silica, approved by the Food and Drug Adminis-
tration (FDA) as Generally Recognized as Safe (GRAS, 21 CFR
Section 573.340) for food and pharmaceutical production, and
classified in the 3rd group of “Not classifiable as to its carcino-
genicity to humans” by the International Agency for Research
on Cancer (IARC).27 Surprisingly, its use in nanomedicine is
still undervalued, and only recently diatomites have been
explored as microcapsules for oral drug delivery, resulting in a
non-cytotoxic biomaterial with high potential to improve the
bioavailability of loaded oral drugs by sustaining the drug
release and enhancing the drug permeability.19 Furthermore,
diatom frustules reduced to NPs were explored as potential
nanocarriers for biomedical applications.28,29 However, diato-
mite powder, due to its sedimentary origin, can contain some
traces of impurities such as organic components and metallic
oxides (MgO, Al2O3, Fe2O3) coming from the environment. As
demonstrated in our previous work,28 a multistep procedure
based on mechanical and chemical purification treatments
was able to remove impurities from frustules, making diato-
mite NPs safer and more biocompatible vehicles for medical
applications. In addition, the biocompatibility of the DNPs
and their capability of transport through cellular membranes
and their use as non-toxic carriers of siRNA inside cancer
cells, has also been demonstrated.29
In the present work, we have investigated the potential of
DNPs as a drug delivery system, improving their stability and
biocompatibility by PEGylation, and cellular internalization by
cell-penetrating peptide (CPP) bioconjugation. Several reports
in the literature have demonstrated the enormous advantages
arising from the use of polymers in the design of drug nano-
carriers, such as the reduction of non-specific aggregation in
aqueous medium and the increase of NPs’ stability, bio-
compatibility, drug loading, and cellular internalization.30–32
The enhancement of the NPs’ cellular uptake is one of the key
issues in drug delivery; however, the cell membranes prevent
drug carriers from entering the cells, unless an active transport
mechanism is involved.33 An efficient approach to deliver
NPs or molecules within the cells is to bind them to peptides
that can cross the cellular membranes, enhancing their trans-
location inside the cells. CPP bioconjugation has been proved
as a valid strategy to improve the intracellular drug delivery of
conventional small drug molecules, NPs or oligonucleotides,
and peptide-based therapeutics, increasing their systemic
diffusion due to the CPP’s property to overcome the lipophilic
barrier of the cellular membranes and deliver these thera-
peutics inside the cells.34,35 Herein, for the first time, a valid
biofunctionalization was able to improve the aqueous stability
of DNPs, enhancing their hemocompatibility, minimizing
their cytotoxicity, and increasing the solubility of a poorly
water-soluble anticancer model drug, sorafenib.
Experimental
Production of diatomite NPs
Diatomite NPs (DNPs) were obtained by mechanical crushing,
sonication, filtering and purification of natural diatomite
(DEREF Spa, Italy), according to the method described in
detail in the ESI and Fig. S1-S3.†
DNP aminosilane functionalization
DNPs were amino-modified by 5% (v/v) 3-aminopropyl-
triethoxysilane (APT, from Sigma-Aldrich, USA) solution in
absolute ethanol (EtOH).36,37 The silanization process was
carried out for 1 h at room temperature (RT) with stirring. The
NP dispersion was centrifuged for 30 min at 13 200 rpm and
the supernatant was removed. The silanized NPs (DNPs-APT)
were then washed twice with EtOH and re-suspended in phos-
phate buffer saline (PBS) (pH 7.4).
DNP PEGylation and peptide bioconjugation
The amino groups of DNPs-APT were covalently conjugated to
the carboxyl groups of HOOC–poly(ethyleneglycol)–NH2
(HOOC–PEG–NH2, average MW ∼ 5000, Jenkem Technology,
USA) by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide-
hydrochloride/N-hydroxysuccinimide (EDC/NHS, Sigma-Aldrich,
USA), and vigorously stirred (800 rpm) overnight (ON) at RT
(Scheme 1, I). The PEGylation of DNPs-APT was carried out by
dispersing DNPs-APT in PEG solution with a ratio of 1 : 2 and
adding EDC (20 mM)/NHS (12 mM) solution to promote the
reaction (ON at RT, 800 rpm). In order to remove the excess of
unconjugated polymer, the PEGylated-NPs (DNPs-APT-PEG)
were extensively rinsed with EtOH and MilliQ-water, and re-
suspended in 2-(N-morpholino)ethanesulfonic acid (MES)
saline buffer. Finally, DNPs-APT-PEG were covalently conju-
gated to the carboxyl groups of a cell penetrating peptide (CPP,
(aminooxy)acetyl-Lys-(Arg)9–COOH, GenicBio, China) in MES
(NPs : CPP 40 : 1) by EDC/NHS, stirring ON at RT (Scheme 1,
II). After the bioconjugation with the CPP-peptide, the NPs
(DNPs-APT-PEG-CPP) were washed twice with MilliQ-water and
re-suspended in Hank’s balanced salt solution (HBSS)–(4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer
(pH 7.4).
Characterization of the DNPs
The hydrodynamic diameter (Z-average), polydispersity index
(PDI) and surface zeta (ζ)-potential of the modified-DNPs were
measured using a Zetasizer Nano-ZS instrument (Malvern
Instruments Ltd, UK). Modified-DNPs were centrifuged and
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re-dispersed in MilliQ-water before each measurement with a
final concentration of 40 µg mL−1.
The surface chemical composition of DNPs before and after
modification was investigated by attenuated total reflectance
Fourier transform infrared spectroscopy (ATR–FTIR). The ATR–
FTIR spectra of all samples were obtained using a Bruker
VERTEX 70 series FTIR spectrometer (Bruker Optics, Germany)
with a horizontal ATR sampling accessory (MIRacle, Pike Tech-
nology, Inc.). The ATR–FTIR spectra were recorded in the wave-
number region of 4000–650 cm−1 with a resolution of 4 cm−1
at RT using OPUS 5.5 software. The measurements were
carried out on dried DNP samples, left to dry prior to the
measurements at RT for 48 h.
The morphology of the bare DNPs was studied using a
transmission electron microscope (TEM, Jeol JEM-1400, Jeol
Ltd, Japan). Samples were prepared in water and dropped on a
carbon coated copper TEM grid before air-drying ON at RT.
DNP fluorescent labelling
Alexa-conjugated DNPs were obtained by using Alexa Fluor®
488 dye (100 µg mL−1 in MES) in a 70 : 1 ratio (DNPs : Alexa) by
EDC/NHS chemistry, stirring for 2 h at RT in the dark. The
labelled DNPs were washed twice with MilliQ-water and stored
in HBSS–HEPES (pH 7.4). The NPs were labelled for confocal
fluorescence microscopy as described below.
Cell culture
MCF-7 and MDA-MB-231 human breast cancer cells were used
as cell models for the in vitro studies. The cell lines were
grown in Dulbecco’s modified Eagle’s and Roswell Park Mem-
orial Institute 1640 media, respectively, as described in detail
in the ESI and Fig. S4.†
Hemotoxicity and red blood cell (RBC) morphological studies
The studies of the hemolytic activity of modified-DNPs and the
RBC morphological changes were carried out according to the
method described in detail elsewhere.38 Heparin-stabilized
fresh human blood was obtained from anonymous donors
from the Finnish Red Cross Blood Service and used within 2 h.
The hemotoxicity of modified-DNPs was estimated at final con-
centrations of 25, 50, 100, and 200 µg mL−1 (200 mL RBCs +
DNPs) and studied at incubation times of 1, 4, 24, 48 h at
RT.38 The morphological changes and DNP–cell interactions
were evaluated by scanning electron microscope (SEM)
imaging. 5% of RBC suspension was incubated with modified-
DNPs (100 µg mL−1) at RT for 4 h. The samples were then
fixed with 2.5% glutaraldehyde at RT for 1 h and treated with
0.1% osmium tetroxide in PBS for 1.5 h. The cells were then
dehydrated in increasing concentrations of 50, 70, 96 and
100% of EtOH for 5, 10, 20, 15 min, respectively. The cell sus-
pensions were then dropped onto coverslips, dried and sputter
coated with platinum before SEM characterization (Zeiss DSM
962, Germany).
Cell viability assay
The biocompatibility and toxicity of the DNPs were assessed by
measuring the adenosine triphosphate (ATP) activity of the
MCF-7 and MDA-MB-231 cells exposed to the bare and modi-
fied-DNPs.39 The ATP concentration was estimated quantitat-
ively using the CellTiter-Glo® luminescent cell viability assay
(Promega, USA). 100 µL of the cell suspensions with a concen-
tration of 2 × 105 cells per mL in the cell media was seeded in
96-well plates and allowed to attach ON. Subsequently, the cell
media were removed and replaced with 100 µL of the DNPs at
concentrations of 25, 50, 100, 200 µg mL−1. After 6 and 24 h of
incubation at 37 °C, 50 µL of the reagent assay and 50 µL of
HBSS–HEPES (pH 7.4) were added to each well. The lumine-
scence of the wells was measured using a Varioskan Flash
(Thermo Fisher Scientific Inc., USA). Negative (HBSS–HEPES,
pH 7.4) and positive (1% of Triton X-100) control wells were
also used and treated similarly as described above. The viabi-
lity of the negative control was taken as 100%. The results are
shown as the average of three independent measurements.
Confocal microscopy imaging
Inverted confocal fluorescence microscopy (Leica SP5 II HCS
A, Germany) was used to evaluate the cellular uptake of the
DNPs into two different breast cancer cell lines, MCF-7 and
MDA-MB-231. In this experiment, each cell line (5 × 104) was
seeded into Lab-Tek™ 8-Chamber Slides (Thermo Fisher
Scheme 1 Schematic representation of the DNPs functionalization. Reaction I, the PEGylation of DNPs-APT (I) via EDC/NHS, under stirring ON at
RT. Reaction II, CPP-peptide bioconjugation of DNPs-APT-PEG via EDC/NHS, under stirring ON at RT. The dual biofunctionalization is based on a
covalent binding between the NPs’ surface and the biomolecules promoted by EDC/NHS chemistry.
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Scientific, USA) in the cell culture media, and allowed to attach
ON at 37 °C. After removing the media, 200 μL of Alexa conju-
gate DNP suspensions (50 μg mL−1) were added to each well
before incubation at 37 °C for 6 (only MCF-7) and 12 h. The
particle suspension was then carefully removed and the walls
were washed twice with HBSS–HEPES buffer (pH 7.4). After
that, the cell membrane was stained by adding 200 μL of Cell-
Mask™ Deep Red plasma membrane stain (3 μg mL−1; Invitro-
gen, USA) for 3 min at 37 °C and washed twice with HBSS–
HEPES buffer (pH 7.4). Finally, the cells were fixed with 2.5%
glutaraldehyde in 0.1 M PBS solution (pH 7.4) for 1 h at RT,
washed twice with HBSS–HEPES buffer and analysed by con-
focal microscopy.
Intracellular distribution by TEM imaging
TEM imaging was used to evaluate the cellular uptake of modi-
fied-DNPs after 12 h of incubation with MCF-7 and
MDA-MB-231 breast cancer cells. For this experiment, 13 mm
round shaped cover slips were placed at the bottom of 24-well
plates (Corning Inc. Life Sciences, USA), and the cells were
seeded in their media and allowed to attach ON. After that, the
cells were washed twice with HBSS–HEPES (pH 7.4) and incu-
bated for 12 h with modified-DNPs (50 µg mL−1) at 37 °C. The
particle suspension was then removed and the cells were
washed twice with HBSS–HEPES. The cells were fixed with
2.5% glutaraldehyde in 0.1 M PBS solution (pH 7.4) for 1 h at
RT. After the fixation, the cells were washed with HBSS–HEPES
(pH 7.4) and sodium cacodylate buffer (NaCac) for 3 min prior
to post-fixation with 1% osmium tetroxide in 0.1 M NaCac
buffer (pH 7.4). The cells were then dehydrated with 30–100%
EtOH for 10 min each and embedded in epoxy resin. Ultrathin
sections (60 nm) were cut parallel to the coverslip, post-stained
with uranyl acetate and lead citrate, and then observed by
TEM.
Drug loading and release
The poorly water-soluble anticancer drug, sorafenib (MW
464.82; LC Laboratories, Boston, USA), was used as a model
drug for the loading degree and release studies, before and
after biofunctionalization of DNPs. The modified-DNPs
were immersed in 10 mg mL−1 of SFN dissolved in acetone
solution with a ratio of 1 mg of particles to 1 mL of drug solu-
tion, and stirred for 2 h at RT. After the drug-loading, the par-
ticles were washed twice with Milli-Q water and the loading
degree was determined by immersing 200 µg of drug-loaded
modified-DNPs in 1 mL of methanol, under vigorous stirring
for 1 h. The amount of drug released was determined by high-
performance liquid chromatography (HPLC, Agilent 1260,
Agilent Technologies, USA) using a column Phenomenex
Gemini (Nx, 3 µm, C18 110 Å). The mobile phase was com-
posed of 0.2% trifluoroacetic acid (pH 2, 42%) and acetonitrile
(58%) with a flow rate of 1.0 mL min−1 and UV-detection set at
a wavelength of 254 nm (25 °C). The in vitro dissolution evalu-
ation was performed dispersing 200 µg of SFN-loaded DNPs in
50 mL of HBSS–HEPES + 10% fetal bovine serum (FBS) at
pH 7.4 and 5.5 and 37 °C, at a stirring speed of 100 rpm.
200 µL of samples was withdrawn from each dissolution test at
different time points. The aliquots were then centrifuged for
3 min at 13 500 rpm and the supernatant was analysed by
HPLC as described above. All measurements were repeated at
least three times.
Statistical analysis
Results of the assays are expressed as mean ± standard devi-
ation (s.d.) of three independent experiments. Results were
evaluated by means of one-way analysis of variance (ANOVA)
with the level of significance set at probabilities of *p < 0.05,
**p < 0.01, and ***p < 0.001 using Origin 8.6 (Origin Lab.
Corp., USA).
Results and discussion
Preparation and characterization of diatomite NPs
The main peculiarities of NPs as drug delivery systems are
their low toxicity, high stability, biocompatibility, and suit-
ability for cellular uptake. In this work, the surface biofunctio-
nalization of DNPs, in order to improve their physicochemical
and biological properties, such biocompatibility and cellular
internalization, was investigated. Purified DNPs were charac-
terized before biofunctionalization by TEM imaging (Fig. 1),
showing a nanometric size and an irregular shape. However, it
was previously demonstrated that the irregular shape of DNPs
does not affect the cell proliferation and morphology.29 As
shown in Fig. 1c and d, the porous structure of the NPs is pre-
served even after the breaking of the diatomite powder in
nanoparticles, where it is clearly visible in the hierarchical
pore organization on the surface of the diatomite NPs and the
mesopores (10 nm < pores diameter < 50 nm) inside macro-
pores (pores diameter > 50 nm). Due to their peculiar porous
nature, diatomite NPs can be very promising for the
loading40,41 of a wide size range of molecules from small mole-
cules to peptides, oligonucleotides, proteins, and antibodies
for the preparation of targeted NPs for drug delivery appli-
cations.41 See the ESI† for more detailed information on the
diatomite NP preparation procedure and characterization.
Polymers are very versatile materials widely used in drug
delivery studies in order to improve the nanocarriers’ pro-
perties such as stability and biocompatibility.42 In order to
obtain an effective DNP PEGylation, the bare NPs were
hydroxylated by Piranha solution, thus increasing the reactivity
of their silica surface, by the introduction of –OH groups. The
covalent bond between PEG and DNPs requires DNP saliniza-
tion using an APT solution,28,29 which introduces the highly
reactive amino groups (–NH2) onto the NP surface that can be
covalently conjugated with the carboxyl groups of PEG mole-
cules using EDC/NHS chemistry (Scheme 1, I). Without this
double-step chemical surface treatment, it would not be poss-
ible to obtain stable covalently-bonded PEG- or CPP-DNP com-
plexes. Due to the polymer solubility in water and in a wide
variety of organic solvents used during the NP modification, it
is crucial that the polymer is covalently bound onto the NP
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surface in order to avoid its untimely detachment.43,44 To
improve the DNPs’ cellular uptake, the free amino groups of
DNPs-APT-PEG were further chemically conjugated with the
carboxyl groups of CPP-peptide, known to highly facilitate the
delivery of cargos (e.g., peptides, proteins, genes, and even
nanoparticles) across the cell membrane,45 by EDC/NHS chem-
istry (Scheme 1, II).
The DNPs were characterized before and after the surface
modification by DLS, analyzing the hydrodynamic diameter,
the PDI, and the surface charge ζ-potential of the particles. An
increase of the particles’ size from 317 ± 8 nm to 364 ± 3 nm
(DNPs-APT) after the APT solution treatment was observed,
confirming the success of the silanization process. A progress-
ive decrease of the nano-aggregates’ size was observed after
PEGylation and CPP bioconjugation. The NPs’ size decreased
from 364 ± 3 nm (DNPs-APT) to 346 ± 4 nm after PEGylation
(DNPs-APT-PEG), and to 340 ± 8 nm after CPP-conjugation
(DNPs-APT-PEG-CPP). This result is due to an increase of the
DNPs’ surface repulsion forces of the modified surface (DNPs-
bare, −19.2 ± 2.0 mV; DNPs-APT, +19.8 ± 3.0 mV; DNPs-
APT-PEG, +35.6 ± 1.5 mV; DNPs-APT-PEG-CPP, +40 ± 2 mV),
which can be attributed to the positive charge of PEG and
CPP-peptide onto the NPs’ surface. As a result, the DNP
stability was improved in aqueous solution and a decrease in
the PDI of the NPs was also observed (Fig. 2).
The chemical silanization, PEGylation and CPP-conjugation
of DNPs were further analysed by ATR–FTIR spectroscopy.
Fig. 3 shows the progressive change of DNP FTIR spectra after
each modification step. All spectra of DNPs showed an intense
band at 1100 cm−1 that corresponds to Si–O–Si bonds, because
silica is the main constituent of the diatomite frustules
(Fig. S5, ESI†). After the silanization process, the DNPs-APT
displayed typical bands of APT corresponding to the CHx
stretching at 2941–2570 cm−1, the bending mode of the free
NH2 at 1630–1470 cm
−1, and the C–N stretching at
1385 cm−1.46,47 After the PEGylation, the DNPs-APT-PEG
showed the stretching bands of CHx at 2960–2849 cm
−1, the
C–H bending vibrations at 2160–1722 cm−1, the amide I band
at 1640 cm−1 associated with the CvO stretching vibration,
the amide II resulting from the N–H bending vibration, and
the C–N stretching vibration at 1580 and 1360 cm−1, respecti-
vely, thus confirming the covalent binding of the PEG mole-
cules onto the NPs’ surface.42,47 After incubation with the
CPP-peptide, the DNPs-APT-PEG-CPP displayed a band at
2984–2881 cm−1 corresponding to the CHx stretching, and at
1930 cm−1 assigned to the C–N stretching of amide II,
Fig. 1 TEM images of bare DNPs (a–c) and increasing zoom of the pores of the NPs (d).
Fig. 2 DNPs ζ-potential and PDI before and after each step of
functionalization determined by DLS at RT.
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confirming the successful CPP-peptide bioconjugation to the
surface of the NPs.47,48
Modified-DNP hemotoxicity
The hemotoxicity study, based on the %-lysed RBCs, is an
important preclinical study to evaluate the level of the NPs’
hemocompatibility, in order to avoid serious risks to human
health (e.g., after intravenous injection of NPs), considering
that the erythrocytes constitute a large volume of the blood.
Moreover, if NPs induce hemolysis, there is a higher risk that
blood constituents can react immunologically to inactivate the
NPs, and thus, affecting their function and increasing their
elimination by macrophages.49,50
In order to evaluate the impact of the modified-DNPs on
RBCs, the hemocompatibility and the morphological studies
of RBCs were determined after exposure to the modified-DNPs
at increasing incubation times (1, 4, 24, and 48 h) and
different NP concentrations (25, 50, 100, and 200 µg mL−1).38
The NP hemotoxicity was qualitatively determined by naked-
eye colour evaluation of the RBCs’ supernatant incubated with
modified-DNPs. The hemotoxicity degree of the DNPs-APT was
higher than that observed for PEG and CPP modified-DNPs,
since the red colour intensity of the DNPs-APT-RBC super-
natant was closer to that of the positive control one (water), as
shown in Fig. 4.
The %-hemolysis determined by spectrophotometric ana-
lysis of the supernatants after 48 h of incubation at the
maximum concentration of modified-DNPs (200 µg mL−1) was
34% for DNP-APT, 7% for DNP-PEG, and 1.3% for CPP-DNP.
This result clearly demonstrated that the biofunctionalization
of the NPs improved the DNP hemocompatibility (Fig. 5).
The morphological changes of the RBCs after exposure to
the modified-DNPs (200 µg mL−1 for 4 h, at RT) were examined
by SEM characterization. The RBCs, in the presence of
DNP-APT, completely altered their morphology, changing from
the biconcave-like disks to a shrunken shape, with consequent
hemolysis (Fig. 6). The DNPs-APT hemotoxicity is attributed to
the free positive amine groups existing on the surface of the
NPs, which strongly interact with the negative charge surface
of the RBCs, resulting in hemolysis and a change of the cell’s
shape.38 In the case of PEGylated particles, no severe change
was observed in the RBC morphology, but the cell membrane
was locally wrapped around with the appearance of small
holes without significant hemolysis. The relevant decrease of
the DNPs-APT hemotoxicity after PEGylation is due to the
improved biocompatibility of the NPs as a result of the
presence of PEG on their surface, which is known to be rela-
tively non-cytotoxic, non-immunogenic, non-antigenic, and to
decrease the protein interaction.51,52 In the case of DNPs-
APT-PEG-CPP, there was no relevant change observed in the
RBCs’ morphology due to the low cytotoxicity of the CPP-
peptide,52 which improved the DNPs’ biocompatibility. There-
fore, both the amino function and also the charge density (the
number and spatial arrangements of the cationic residues) are
important factors for toxicity.53 A three-point attachment is
necessary for eliciting a biological response on cell mem-
branes and the activity of a molecule decreases when the space
between reactive amino groups increases in the primary struc-
ture.54 The arrangement of cationic charges on the molecular
structure determines the accessibility of the charges to the cell
surface.53 Our study confirms these observations, where APT
showed more toxicity than PEG and CPP, due to the simple
molecular structure formed by the short amino-alkyl chains of
Fig. 3 ATR–FTIR spectra of the modified-DNPs. DNPs were character-
ized before the biofunctionalization (black line), after the silanization
process (red line), after the PEGylation (blue line), and also after the
CPP-peptide bioconjugation (green line). (a) indicates CHx stretching
vibration, (b) the bending mode of the free NH2, (c) the C–N stretching,
(d) the C–H bending vibrations, and (f-I and f-II) N–H bending vibration
and the C–N stretching vibration, respectively.
Fig. 4 Representative pictures of the RBCs after interaction with the
modified-DNPs. The DNPs were incubated with the cells for 48 h and at
different concentrations (25, 50, 100, and 200 µg mL−1).
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APT, and thus, more accessibility of amino groups to interact
with the cells. As shown in Fig. 6, very small amounts of APT-
and PEG-modified DNPs (indicated by white arrows) were
adsorbed onto the RBCs’ surface, while a considerable amount
was observed for CPP-DNPs, thus this biofunctionalization sig-
nificantly improved the DNPs–cell membrane interactions.
In vitro cell viability assay
The ATP-content was used for the evaluation of the bare and
modified-DNP cytotoxicity on MCF-7 and MDA-MB-231 breast
cancer cells, after 6 and 24 h of incubation time at different
DNP concentrations (25, 50, 100, and 200 µg mL−1). The
exposure of MCF-7 and MDA-MB 231 cells to increasing con-
centrations of bare diatomite NPs within 24 h of incubation
time induced very low toxicity, demonstrating their potential
applicability as nanovectors in nanomedicine (Fig. S4, ESI†).
The modified-NPs showed the same degree of cytotoxicity on
both cell lines, as shown in Fig. 7. The DNPs-APT showed sig-
nificant cytotoxic activity after 6 h of incubation and at lower
concentrations (25 µg mL−1). Increasing the incubation time
and the NP concentration resulted in an increased cytotoxicity
of the NPs. After PEGylation and CPP-bioconjugation to the
DNPs-APT, the cytotoxicity was significantly decreased after
24 h of incubation compared to the negative control (HBSS–
HEPES, pH 7.4). In addition, no significant dependency on the
exposure time and NP concentration was observed for the cyto-
toxicity of the PEGylated and CPP-biofunctionalized NPs. The
toxicity of DNPs-APT can be attributed to the positive charge of
free amino groups of APT, as discussed previously. These
results are in agreement with the hemotoxicity data (Fig. 4),
confirming an increase in the DNPs’ biocompatibility after the
functionalization with PEG and biofunctionalization with the
CPP-peptide. These results further suggest that DNPs-
APT-PEG-CPP could be used as nanocarriers for long incu-
bation times and high concentrations.
Cellular uptake of the modified-DNPs
Another key requirement of the nanocarriers for drug delivery
is the cellular internalization into cancer cells without dama-
ging the cellular integrity of healthy cells; therefore, the
surface chemistry of the NPs has a significant impact on the
NP performance in biomedical applications. Several peptides,
Fig. 5 Hemocompatibility of the modified-DNPs. Hemotoxicity of APT-, PEG- and CPP- modified DNPs incubated for 48 h at different concen-
trations (25, 50, 100, and 200 µg mL−1) with RBCs, estimated by spectrophotometric methods (577 nm) to analyse the amount of lysed-hemoglobin
in the supernatants. The insert figures show the magnifications of the graphs. Statistical analysis was performed by ANOVA. The level of significance
from the negative control was set as probabilities of *p < 0.05, **p < 0.01 and ***p < 0.001. Error bars represent s.d. (n = 3).
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capable of translocation in cellular membranes, have been
used to improve the NPs’ cellular uptake.55,56 The CPP-peptide
used in the present study consists of a short basic amino acid
sequence with a net positive charge sequence and has the
ability to facilitate the delivery into the cells of various mole-
cular cargos, such as oligonucleotides, small molecules,
siRNA, NPs, peptides and proteins.57
The cellular uptake was evaluated by confocal fluorescence
microscopy after DNP and cellular membrane labelling with
Alexa Fluor-488® and CellMask™ Deep Red, respectively.
Initially, the cellular internalization of modified-DNPs was
evaluated on MCF-7 at two different incubation times (6 and
12 h) in order to determine the time required for a satisfactory
uptake. The best incubation time, regardless of the modified-
DNP type was 12 h, while the NPs were localized prevalently in
the cellular membranes after 6 h. In both the cell lines, an
increase in the NPs’ cellular uptake after CPP-bioconjugation
was observed, as shown in Fig. 8. The merge images of the
CPP modified-DNPs showed a yellow colour, resulting from the
co-localization of the green labelled-DNPs and the red colour
of cell membranes, which indicates the presence of the NPs
inside the cells. In the case of the APT-modified NPs, more cel-
lular uptake was observed compared to the NPs functionalized
with PEG, due to the presence of the free amino groups of
APT.
The cellular uptake was also evaluated by TEM imaging of
both cancer cells after 12 h of incubation with the modified-
DNPs (50 µg mL−1), confirming the results obtained for the
confocal fluorescence microscopy studies. In Fig. 9, the APT-
modified DNPs were mainly localized in the proximity of the
cell membrane, while in the case of the DNPs-APT-PEG no sig-
nificant cellular uptake was observed. For the CPP-modified
NPs, a considerable amount of DNPs was internalized into the
cells with a homogeneous distribution in the cytoplasm and
very close to the nucleus. All these results confirmed that CPP
bioconjugation is a valid functionalization strategy to increase
the cell penetration of diatomite NPs. The benefit of CPP on
the surface of the NPs is the ability to translocate into the
intracellular compartment without causing any cell membrane
damage, resulting in low cytotoxicity and high uptake
efficiency.58–60
Drug loading and release studies
The ultimate goal of targeted drug delivery is to deliver the
administered drug to the target, while eliminating or minimiz-
ing the accumulation of the drug at any non-target site with
minimal side effects.61 In this context, the poorly water-soluble
anticancer drug, sorafenib (SFN), was used as a model drug to
investigate the loading efficacy in the modified-DNPs and the
release profiles in aqueous buffer solutions at pH 7.4 and 5.5,
mimicking the physiological and intratumoral pH, respecti-
vely. The multikinase inhibitor, SFN, is considered a promis-
ing targeted protein kinase agent for the treatment of a broad
range of cancers due to its significant in vitro and in vivo anti-
tumor activity, resulting in the tumor growth inhibition and
disruption of tumor microvasculature through antiprolifera-
Fig. 6 SEM pictures of the RBCs’ morphological modification after the exposure to the modified-DNPs. The modified DNPs (100 µg mL−1) were
incubated with RBCs for 4 h at RT. The DNPs-APT showed the higher toxicity than the PEG and CPP-modified DNPs, resulting in severe morphologi-
cal changes in the cell. The CPP-bioconjugation improved significantly the DNP–cell membrane interactions, as indicated by white arrows. Scale
bars are 3 µm.
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Fig. 7 Cell viability of MCF-7 (a and b) and MDA-MB-231 (c and d) cells after exposure to the modified-DNPs at different concentrations. Statistical
analysis was made by ANOVA comparing all data sets to the negative control HBSS (pH 7.4). The HBSS–HEPES (pH 7.4) and Triton X-100 were used
as negative and positive controls, respectively. The level of significance was set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars
represent s.d. (n = 3).
Fig. 8 Confocal fluorescence microscopy of MCF-7 (a) and MDA-MB-231 (b) cells treated with APT, APT-PEG, APT-PEG-CPP modified-DNPs for
12 h at 37 °C. CellMask® (red) and Alexa Fluor-488® (green) were used to label the cell membrane and the DNPs, respectively. The merge figures
are obtained by overlapping the DNP and the cell membrane images, allowing the determination of whether the NPs are located outside (green
colour) or inside (yellow colour) the cells.
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tive, antiangiogenic, and/or proapoptotic effects.62,63 Firstly,
the loading degree of SFN in APT-, PEG-, CPP-modified DNPs
was evaluated in order to determine the influence of the
surface biofunctionalization on the drug loading. The loading
degree of SFN was 10.4 ± 1.1% in the DNPs-APT, 22 ± 2% in
the DNPs-APT-PEG, and 17 ± 2% in the DNPs-APT-PEG-CPP.
Fig. 9 TEM images of MCF-7 (a) and MDA-MB-231 (b) cells treated with 50 µg mL−1 of DNPs-APT, DNPs-APT-PEG, and DNPs-APT-PEG-CPP for
12 h at 37 °C. A very small amount of APT- and PEG-modified DNPs was found inside the MCF-7 and MDA-MB-231 cells. In the case of DNPs-
APT-PEG-CPP, a considerable amount of the NPs was observed inside the cells. Scale bars are 10 µm.
Fig. 10 Drug release profiles of the SFN-loaded DNPs in HBSS–HEPES + 10% FBS at pH 7.4 (a) and pH 5.5 (b) at 37 °C. Values represent the mean ±
s.d. (n = 3).
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The surface biofunctionalization improved the drug loading,
entrapping higher amounts of the drug into the modified
DNPs than in APT alone. In the case of PEG-modified DNPs,
an higher amount of the drug was loaded than in DNPs-APT,
probably due to weak interactions (e.g., van der Waals forces)
between PEG and the SFN.64 The CPP-conjugation step, even if
it requires ON bioconjugation time and several washes after
the reaction, causes only a very small decrease in the drug
loading, possibly due to some removal of the adsorbed PEG
molecules that are not covalently bound to the NP surface. The
release profiles of SFN were assessed in HBSS–HEPES + 10%
FBS solution at pH 7.4 and 5.5 (Fig. 10). The dissolution of
pure SFN within 24 h (data not shown) in aqueous solution
(pH 7.4 and 5.5) was negligible. In the case of SFN-loaded in
APT- and CPP-modified DNPs, the drug release in both buffer
solutions (pH 7.4 and 5.5) was gradual and constant within
4 h. SFN is characterized by its very poor water solubility, and
the results show that the surface modification of DNPs
improved the solubility of the drug in aqueous solution, but
the functionalization of DNPs with CPP did not significantly
influence the release profile of the loaded drug. However, in
view of DNPs’ use for in vivo drug release and anticancer
studies, it should be recommended that CPP-modified DNPs
be used for the remarkable results of stability, biocompatibility
and cellular uptake obtained here.
Conclusions
In this work, we exploited the great potential of a natural
porous silica NP derived from diatomite as a drug delivery
system for cancer therapy applications. The preparation of NPs
with suitable biocompatibility, stability in aqueous solution
and cellular uptake by covalent conjugation of PEG and the
CPP-peptide onto the NPs’ surface, was reported. Two step
surface modifications of DNPs-APT by covalent attachment of
PEG and bioconjugation with the CPP peptide allowed not
only the reduction in the PDI and the enhancement of the
NPs’ stability in aqueous solution, but also the improvement
of the NPs’ cellular uptake and their enhanced biocompatibil-
ity, resulting in a decreased hemotoxicity and cytotoxicity of
RBCs and breast cancer cells (MCF-7 and MDA-MB-231),
respectively. The drug loading and drug release studies indi-
cated that the NPs’ surface functionalization improved the
loading capacity of DNPs (up to 22%) and provided the sus-
tained release of the poorly water-soluble anticancer drug SFN.
Overall, we demonstrated that the low toxicity, the optimal cel-
lular uptake, and the drug loading and release properties
make DNPs-APT-PEG-CPP a promising nanovector for cancer
therapy. In conclusion, herein we demonstrated the potential
of cheap, natural and biocompatible DNPs as a valid alterna-
tive to synthetic NPs and effective biofunctionalized nanovec-
tors for superior intracellular localization and drug delivery in
cancer cells, with future perspectives to develop bioengineered
DNPs for localized drug delivery applications.
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